Early trial halted after testing Radiation-Immunotherapy combo for tough lung cancers
NCT ID NCT03436056
Summary
This early-stage trial aimed to test the safety of combining a type of targeted, high-dose radiation (lung SBRT) with an immunotherapy drug (pembrolizumab) for patients with advanced non-small cell lung cancer that had worsened after standard treatments. The study planned to find the safest radiation dose to use with the drug. It was terminated early, having enrolled only 2 of a planned 24 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.